This website uses cookies to improve the site and user experience. By continuing to browse this site,
you agree to accept our use of cookies. For more information, please review our Cookies Policy
Development PipelineBrentuximab vedotin
an antibody–drug conjugate directed to CD30 being investigated in certain lymphomas and solid tumors
The safety and efficacy of these investigational compounds, or investigational uses of marketed products, have not been established. For an agent(s) whose safety and efficacy has not been established or confirmed, future regulatory approval or commercial availability is not guaranteed.
Clinical Trials
ECHELON-3: Diffuse large B-cell lymphoma
-
Phase 1
-
Phase 2
-
Phase 3
CheckMate 744: AYA CD30+ Hodgkin lymphoma
-
Phase 1
-
Phase 2
-
Phase 3
SGN35-027: Early and advanced stage Hodgkin lymphoma
-
Phase 1
-
Phase 2
-
Phase 3
SGN35-032: CD30-low and -negative peripheral T-cell lymphoma
-
Phase 1
-
Phase 2
-
Phase 3
SGN35-033: Metastatic non-small cell lung cancer, melanoma, and squamous cell carcinoma of the head and neck
-
Phase 1
-
Phase 2
-
Phase 3
Program Resources
High-level synopsis of brentuximab vedotin and ongoing clinical trials
Detailed information about brentuximab vedotin clinical trials
Related Videos
Brentuximab Vedotin in Combination with Nivolumab Proposed Mechanism of Action